Zeta CD45RB Antibody. Zeta’s recombinant rabbit antibody recognizes CD45RB (LCA), which is useful in the differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms. CD45 (PTPRC), has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. According to cell type, multiple isoforms of CD45R are distributed throughout the immune system. These isoforms arise because of alternative splicing of exons 4, 5, and 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4), CD45RB (exon 5), CD45RC (exon 6), and CD45RO (exons 4 to 6 spliced out). The variation in these isoforms is localized to the extracellular domain of CD45R, while the intracellular domain is conserved. CD45R functions as a phosphor-tyrosine phosphatase. Antibody to CD45 is useful in the differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms.
CD45RB is similar to CD45 although not expressed in Langerhans cells and some T-cells while B cells, most Tcells, monocytes, macrophages and ganulocytes exhibit weak expression. Additionally, CD45RB is not expressed in platelets, plasma cell neoplams, some lymphoblastic lymphomas and some analaplastic large cell lympomas. Finally, CD4+, CD45RB high T cells are present in inflammatory bowel disease and may be important in pathogenesis as they produce more proinflammatory cytokines than CD4+ CD45RB low T cells.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.